Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
US10494433B2 · kind B2 · utility
1Cited by
2References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 5, 2014 |
| Grant date | Dec 3, 2019 |
| Priority date | — |
| Expiry date | Nov 5, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/90
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.